Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Collegium Pharmaceutical Inc (COLL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Collegium Pharmaceutical's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
35.94 +1.20    +3.45%
23/04 - Closed. Currency in USD ( Disclaimer )
After Hours
36.68
+0.74
+2.06%
19:59:50 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 559,415
  • Bid/Ask: 34.54 / 36.69
  • Day's Range: 34.92 - 36.51
Collegium Pharmaceutical 35.94 +1.20 +3.45%

Collegium Pharmaceutical Inc Company Profile

 
Get an in-depth profile of Collegium Pharmaceutical Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

207

Equity Type

ORD

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Contact Information

Address 100 Technology Center Drive Suite 300
Stoughton, 02072
United States
Phone 781 713 3699
Fax 781 828 4697

Top Executives

Name Age Since Title
Gino Santini 64 2012 Lead Independent Director
Joseph J. Ciaffoni 50 2017 President, CEO & Director
John Gordon Freund 67 2014 Independent Director
Gwen A. Melincoff 70 2017 Independent Director
Rita J. Balice-Gordon 61 2020 Independent Director
Neil F. McFarlane 49 2022 Independent Director
Charles E. Argoff - - Scientific Advisor
Robert H. Dworkin - - Scientific Advisor
William T. Zempsky - - Scientific Advisor
Garen G. Bohlin 76 2015 Independent Director
Bill McCarberg - - Scientific Advisor
Cynthia G. McCormick - - Scientific Advisor
Srinivas Nalamachu - - Scientific Advisor
Lynn R. Webster - - Scientific Advisor
Joseph V. Pergolizzi 53 - Scientific Advisor
Richard L. Rauck - - Scientific Advisor
John A. Fallon 75 2016 Independent Director
Nathaniel P. Katz - - Scientific Advisor
Michael Thomas Heffernan 60 2002 Co-Founder & Independent Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

COLL Comments

Write your thoughts about Collegium Pharmaceutical Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jeff Bailey
JeffB Dec 23, 2022 10:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
COLL $22.96 @ Friday Close!
Todd Masus
Todd Masus May 10, 2022 5:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Horrible analyst coverage, lame stock performance, management focused on everything but making money.
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Feb 14, 2022 6:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
adedded at 17.57 lets goooooooooooo
Yael Aviv
Yael Aviv Dec 28, 2020 6:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
H.C. Wainwright & Co upgraded ABEO to a buy while lowering price target from $11 to $8. 11/25/2020
Jeff Bailey
JeffB Jan 07, 2019 4:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lackluster 2019 guidance. $15.06
Jeff Bailey
JeffB Jun 20, 2018 6:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looking for a weekly close above $29.87.  COLL continues to impress after recent weekly interval close above $25.06.. . https://invst.ly/7sw4y
Joe Joe
Joe Joe Jun 20, 2018 6:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$15 now.
Jeff Bailey
JeffB Jun 20, 2018 6:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Joe Joe Never could get the close could it?  Great test!!!!  Keep on trading!
Jeff Bailey
JeffB Jun 11, 2018 3:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Could be setting up for a move higher!. . https://invst.ly/7pfk2
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email